Literature DB >> 26984240

Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations.

Judith A E M Zecha1, Judith E Raber-Durlacher1,2, Raj G Nair3, Joel B Epstein4,5, Stephen T Sonis6, Sharon Elad7, Michael R Hamblin8,9,10, Andrei Barasch11, Cesar A Migliorati12, Dan M J Milstein1, Marie-Thérèse Genot13, Liset Lansaat14, Ron van der Brink15, Josep Arnabat-Dominguez16, Lisette van der Molen14, Irene Jacobi14, Judi van Diessen17, Jan de Lange1, Ludi E Smeele1,14, Mark M Schubert18, René-Jean Bensadoun19.   

Abstract

PURPOSE: There is a large body of evidence supporting the efficacy of low level laser therapy (LLLT), more recently termed photobiomodulation (PBM), for the management of oral mucositis (OM) in patients undergoing radiotherapy for head and neck cancer (HNC). Recent advances in PBM technology, together with a better understanding of mechanisms involved, may expand the applications for PBM in the management of other complications associated with HNC treatment. This article (part 1) describes PBM mechanisms of action, dosimetry, and safety aspects and, in doing so, provides a basis for a companion paper (part 2) which describes the potential breadth of potential applications of PBM in the management of side-effects of (chemo)radiation therapy in patients being treated for HNC and proposes PBM parameters.
METHODS: This study is a narrative non-systematic review.
RESULTS: We review PBM mechanisms of action and dosimetric considerations. Virtually, all conditions modulated by PBM (e.g., ulceration, inflammation, lymphedema, pain, fibrosis, neurological and muscular injury) are thought to be involved in the pathogenesis of (chemo)radiation therapy-induced complications in patients treated for HNC. The impact of PBM on tumor behavior and tumor response to treatment has been insufficiently studied. In vitro studies assessing the effect of PBM on tumor cells report conflicting results, perhaps attributable to inconsistencies of PBM power and dose. Nonetheless, the biological bases for the broad clinical activities ascribed to PBM have also been noted to be similar to those activities and pathways associated with negative tumor behaviors and impeded response to treatment. While there are no anecdotal descriptions of poor tumor outcomes in patients treated with PBM, confirming its neutrality with respect to cancer responsiveness is a critical priority.
CONCLUSION: Based on its therapeutic effects, PBM may have utility in a broad range of oral, oropharyngeal, facial, and neck complications of HNC treatment. Although evidence suggests that PBM using LLLT is safe in HNC patients, more research is imperative and vigilance remains warranted to detect any potential adverse effects of PBM on cancer treatment outcomes and survival.

Entities:  

Keywords:  Chemotherapy; Head and neck cancer; LLLT and PBM; Low level laser therapy; Low level light therapy; Mucositis; Orofacial complications; Photobiomodulation; Radiation therapy; Safety

Mesh:

Year:  2016        PMID: 26984240      PMCID: PMC4846477          DOI: 10.1007/s00520-016-3152-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  99 in total

1.  Low level laser therapy (LLLT) and World Association for Laser Therapy (WALT) dosage recommendations.

Authors:  Jan Magnus Bjordal
Journal:  Photomed Laser Surg       Date:  2012-01-10       Impact factor: 2.796

2.  Effects of pre-radiation exposure to LLLT of normal and malignant cells.

Authors:  Andrei Barasch; Judith Raber-Durlacher; Joel B Epstein; James Carroll
Journal:  Support Care Cancer       Date:  2015-12-16       Impact factor: 3.603

3.  Effect of laser rays on wound healing.

Authors:  E Mester; T Spiry; B Szende; J G Tota
Journal:  Am J Surg       Date:  1971-10       Impact factor: 2.565

Review 4.  Multiple roles of cytochrome c oxidase in mammalian cells under action of red and IR-A radiation.

Authors:  Tiina I Karu
Journal:  IUBMB Life       Date:  2010-08       Impact factor: 3.885

5.  Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.

Authors:  Yoko Nagata; Akihisa Takahashi; Ken Ohnishi; Ichiro Ota; Takeo Ohnishi; Takashi Tojo; Shigeki Taniguchi
Journal:  Int J Oncol       Date:  2010-10       Impact factor: 5.650

Review 6.  Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients.

Authors:  Stephen T Sonis; Sepehr Hashemi; Joel B Epstein; Raj G Nair; Judith E Raber-Durlacher
Journal:  Oral Oncol       Date:  2016-02-03       Impact factor: 5.337

Review 7.  Functional outcomes and rehabilitation strategies in patients treated with chemoradiotherapy for advanced head and neck cancer: a systematic review.

Authors:  Lisette van der Molen; Maya A van Rossum; Lori M Burkhead; Ludi E Smeele; Frans J M Hilgers
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-09-30       Impact factor: 2.503

Review 8.  Targeted therapies in head and neck cancer: past, present and future.

Authors:  Alexander D Rapidis; Jan B Vermorken; Jean Bourhis
Journal:  Rev Recent Clin Trials       Date:  2008-09

9.  Low-level laser irradiation attenuates production of reactive oxygen species by human neutrophils.

Authors:  Yuji Fujimaki; Tadashi Shimoyama; Qiang Liu; Takashi Umeda; Shigeyuki Nakaji; Kazuo Sugawara
Journal:  J Clin Laser Med Surg       Date:  2003-06

10.  The effect of low-level laser irradiation (In-Ga-Al-AsP - 660 nm) on melanoma in vitro and in vivo.

Authors:  Lúcio Frigo; Juliana S S Luppi; Giovani M Favero; Durnavei A Maria; Sócrates C Penna; Jan M Bjordal; Rene J Bensadoun; Rodrigo A B Lopes-Martins
Journal:  BMC Cancer       Date:  2009-11-20       Impact factor: 4.430

View more
  48 in total

1.  Long-term safety of photobiomodulation therapy for oral mucositis in hematopoietic cell transplantation patients: a 15-year retrospective study.

Authors:  Letícia Mello Bezinelli; Luciana Corrêa; Cristina Vogel; Jose Mauro Kutner; Andreza Feitosa Ribeiro; Nelson Hamerschlak; Carlos de Paula Eduardo; Cesar Augusto Migliorati; Fernanda de Paula Eduardo
Journal:  Support Care Cancer       Date:  2021-05-22       Impact factor: 3.603

2.  Photobiomodulation therapy in the management of oral mucositis: search for the optimal clinical treatment parameters.

Authors:  Sharon Elad; Praveen Arany; Rene-Jean Bensadoun; Joel B Epstein; Andrei Barasch; Judith Raber-Durlacher
Journal:  Support Care Cancer       Date:  2018-05-22       Impact factor: 3.603

3.  Treatment of mucositis with combined 660- and 808-nm-wavelength low-level laser therapy reduced mucositis grade, pain, and use of analgesics: a parallel, single-blind, two-arm controlled study.

Authors:  Raquel Gusmão Soares; Lucyana Conceição Farias; Agna Soares da Silva Menezes; Carla Silvana de Oliveira E Silva; Angeliny Tamiarana Lima Tabosa; Pablo Vinicyus Ferreira Chagas; Laís Santiago; Sérgio Henrique Sousa Santos; Alfredo Maurício Batista de Paula; André Luiz Sena Guimarães
Journal:  Lasers Med Sci       Date:  2018-06-15       Impact factor: 3.161

4.  Preliminary study in a new protocol for the treatment of oral mucositis in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) and chemotherapy (CT).

Authors:  Marina Consuelo Vitale; Carola Modaffari; Nunzia Decembrino; Feng Xiao Zhou; Marco Zecca; Patrizia Defabianis
Journal:  Lasers Med Sci       Date:  2017-06-29       Impact factor: 3.161

5.  Effect of photobiomodulation on CCC-ESF reactive oxygen species steady-state in high glucose mediums.

Authors:  Hongli Chen; Mengru Tu; Jia Shi; Yunhao Wang; Zhenhao Hou; Jinhai Wang
Journal:  Lasers Med Sci       Date:  2020-07-09       Impact factor: 3.161

6.  Management of radiation-induced mucosal necrosis with photobiomodulation therapy.

Authors:  Caroline de Bataille; Vincent Sibaud; Angélique Prioul; Anne Laprie; Emmanuelle Vigarios
Journal:  Support Care Cancer       Date:  2017-10-09       Impact factor: 3.603

7.  Photobiomodulation therapy: management of mucosal necrosis of the oropharynx in previously treated head and neck cancer patients.

Authors:  Joel B Epstein; Paul Y Song; Allen S Ho; Babak Larian; Arash Asher; Rene-Jean Bensadoun
Journal:  Support Care Cancer       Date:  2016-12-17       Impact factor: 3.603

Review 8.  Photobiomodulation for traumatic brain injury and stroke.

Authors:  Michael R Hamblin
Journal:  J Neurosci Res       Date:  2017-11-13       Impact factor: 4.164

9.  The dental management of a mouth cancer patient.

Authors:  N G Beacher; M P Sweeney
Journal:  Br Dent J       Date:  2018-11-09       Impact factor: 1.626

10.  Photobiomodulation therapy in the management of chronic oral graft-versus-host disease.

Authors:  Joel B Epstein; Judith E Raber-Durlacher; Michael Lill; Yuliya P L Linhares; Jerry Chang; Andrei Barasch; Romée I C Slief; Margot Geuke; Judith A E M Zecha; Dan M J Milstein; D Tzachanis
Journal:  Support Care Cancer       Date:  2016-09-21       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.